Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Is rapamycin an effective longevity drug? — Whalespan

Content›Video›Is rapamycin an effective lo…

Is rapamycin an effective longevity drug?

Peter Attia9m · 2024-05-12

Claims Made

13

Claims Supported

6

Support Rate

46%

Support rate

6 of 13 claims supported

6 supported7 partial / not

Claims from this content

9

✓Well SupportedPharmacologic inhibition of mTOR with rapamycin or its analogs shows promise for lifespan and healthspan improvement, even when initiated late in life.✓Well SupportedRapamycin was discovered in the mid-1960s from Streptomyces hygroscopicus found on Easter Island and was initially identified as a potent antifungal.✓Well SupportedRapamycin's life-extending effects have been replicated across various model systems, including yeast, fruit flies, and worms.◐Partially SupportedThe difference between rapamycin's immunosuppressive and geroprotective effects is likely due to dosage and frequency.Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

◐

The rapamycin study in dogs had a target of 40 dogs, but only 24 completed the study due to exclusions for heart disease and one owner discontinuing medication.

◐Partially SupportedPeter Attia prescribes rapamycin to fewer than 10% of his patients due to the need for them to understand the risks, probabilities, and uncertainties involved.

✓Well SupportedRapamycin was approved by the FDA in 1999 as a frontline treatment for organ transplant patients.

?Limited ResearchThe optimal dosing schedule for rapamycin (daily vs. weekly vs. every other week) and the required duration of dosing are poorly explored, even in mouse studies.

◐Partially SupportedGeroprotective drugs act broadly across hallmarks of aging, even if their mechanisms are not fully understood.